AOD-9604 (2 mg Vial) Dosage Protocol

Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).

• Peptide Vials (AOD-9604, 2 mg each):
  • 8 weeks: approximately 12 vials required
  • 12 weeks: approximately 19 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (12 vials): 36 mL - 4 bottles required (10 mL each)
  • 12 weeks (19 vials): 57 mL - 6 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)

AOD-9604 2 mg

View Supplier

U-100 syringes (1 mL capacity; check graduations)

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
• Typical daily range: 300–500 mcg once daily (gradual titration).
• Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

AOD-9604 dosage protocols leverage this synthetic 16‑amino‑acid fragment (Tyr‑hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without elevating IGF‑1 levels or causing insulin resistance^[1][2]. Clinical trials have demonstrated that AOD‑9604 exhibits a placebo‑like safety profile in obese adults, making it a well‑tolerated option for metabolic support^[3]. This educational protocol outlines a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

AOD-9604 is a synthetic peptide: a 16-amino-acid peptide fragment derived from the C-terminal region of human growth hormone. It is also described in research as Tyr-hGH 177-191 or LAT8881. AOD-9604 is not full-length human growth hormone, and its regulatory status is clear: AOD-9604 is not FDA-approved. FDA’s current review identifies limited route-specific safety data, unresolved peptide-characterization questions, and potential immunogenicity concerns for compounded AOD-9604.^[1][2]

• Exact vial strength: This page calculates from a 2 mg vial prepared to a 3.0 mL final volume.
• Resulting concentration: 2 mg divided by 3.0 mL equals approximately 0.667 mg/mL, or 667 mcg/mL.
• U-100 conversion: One unit is 0.01 mL and contains approximately 6.67 mcg at this concentration.
• Evidence boundary: The 300 mcg and 500 mcg chart rows above are community-reported calculation examples. They are not an FDA-approved regimen or a schedule validated by a subcutaneous human trial.

The AOD-9604 2 mg dosage calculation begins with the vial strength and final liquid volume. The chart places peptide mass, U-100 units, mL, frequency, and duration together so each row can be read without a second conversion table.

2 mg ÷ 3.0 mL = 0.667 mg/mL. Desired amount ÷ 667 mcg/mL = injection volume. Injection volume × 100 = U-100 units.

• 300 mcg equals approximately 0.45 mL, or 45 units on a U-100 syringe.
• 500 mcg equals approximately 0.75 mL, or 75 units on a U-100 syringe.
• One U-100 unit is a 0.01 mL volume marking, not a peptide international unit.
• The calculation changes if either the vial strength or final volume changes, even when the target peptide mass stays the same.

A peptide calculator can reproduce this arithmetic, but it cannot select an AOD-9604 dose, determine suitability, or convert a community-reported schedule into clinical evidence. For reconstituted AOD-9604, the exact vial strength matters because a 2 mg AOD-9604 vial produces different syringe volumes and vial yield than a 5 mg vial.

Vial strength does not change the identity of AOD-9604, but it does change preparation math. At a 3.0 mL final volume, the 2 mg vial is less concentrated than the 5 mg vial. A 300 mcg calculation therefore occupies 0.45 mL rather than 0.18 mL, while a 500 mcg calculation occupies 0.75 mL rather than 0.30 mL.

The same distinction affects vial yield. A 2 mg vial contains four 500 mcg amounts or about six full 300 mcg amounts, with peptide remaining after the sixth 300 mcg calculation. Those figures are inventory arithmetic, not instructions to administer AOD-9604. The Supplies Needed card above calculates vial counts for the displayed planning periods.

AOD-9604 was designed from the lipolytic region of human growth hormone while researchers explored whether metabolic effects could be separated from the growth-promoting activity associated with the full hormone. This fragment of human growth hormone contains 16 amino acid residues. Published sources use several related labels, including AOD9604, Tyr-hGH 177-191, hGH 176-191, and LAT8881.^[3][4]

These terms should not be used to treat AOD-9604 and human growth hormone as interchangeable. Sequence, formulation, route, concentration, and exposure all affect how a study can be interpreted. The 2 mg label on this page identifies the amount in the vial; it does not establish potency, purity, sterility, stability, or an approved indication.

A 2013 publication summarized six randomized, double-blind, placebo-controlled AOD-9604 clinical trials involving 893 participants. Early studies used intravenous infusion and later studies used oral doses. The publication reported no consistent increase in IGF-1, no adverse effect on oral glucose-tolerance testing, and no detected antibodies against the peptide in the tested participants.^[3]

Those findings do not validate the subcutaneous schedule displayed on this page. The study authors disclosed financial interests, the article summarized development-program data, and the tested routes differ from the community-reported subcutaneous use shown in the chart. FDA’s later review stated that it found no human information for proposed subcutaneous and transdermal uses.^[1]

Route is not a minor detail. Oral, intravenous, intra-articular, and subcutaneous administration can produce different exposure, formulation, sterility, and immunogenicity questions. Evidence from one route cannot automatically establish a dose or safety profile for another.

AOD-9604 was investigated in obesity research, but the development program did not produce an approved weight-loss treatment. An official ClinicalTrials.gov protocol for a later LAT8881 study states that phase 2 obesity studies did not demonstrate statistically significant weight loss compared with placebo and that development for obesity was discontinued.^[5]

This history matters when interpreting searches for AOD-9604 dosage for weight loss, fat-loss peptide dosing, or AOD-9604 results. The 2 mg vial calculation can show how much peptide is represented by a syringe volume. It cannot establish that 300 mcg, 500 mcg, or another amount causes clinically meaningful fat loss, preserves muscle, targets abdominal fat, or improves metabolic health.

Early animal research examined whether AOD-9604 could influence lipolysis, fat metabolism, and other metabolic effects. In obese Zucker rats, researchers reported metabolic activity without the same insulin-sensitivity effect observed with full-length growth hormone.^[4] A separate mouse study associated chronic exposure with changes in body weight, body fat mass, fat-cell sensitivity, and beta-3 adrenergic-receptor expression.^[6]

These are preclinical findings. Animal dose, route, metabolism, and experimental conditions cannot be converted directly into a human AOD-9604 dosing protocol. The mouse study also suggested that the proposed mechanism was more complex than a simple direct beta-3 receptor effect, so claims that the peptide merely “switches on fat burning” go beyond what the data establish.^[6]

A rabbit osteoarthritis study evaluated intra-articular AOD-9604, with or without hyaluronic acid, in a collagenase-induced knee model. The researchers reported histologic and functional differences among the animal groups.^[7]

That experiment does not support the subcutaneous dosage chart above. It used a different species, disease model, route, formulation context, and research objective. It is relevant to the broader research map, but it does not establish a cartilage-repair indication, a systemic injection schedule, or a calculation for a 2 mg research vial.

AOD-9604 is not FDA approved and has no FDA approval for weight loss or another therapeutic use. FDA’s Pharmacy Compounding Advisory Committee materials describe limited clinical safety information, no identified pharmacokinetic or bioavailability information for any route, no human data for proposed subcutaneous AOD-9604 use, and unresolved concerns about peptide impurities, aggregation, product characterization, and immunogenicity.^[1]

FDA also lists AOD-9604 among bulk substances that may present significant safety risks in compounding and notes that serious adverse events have been identified, although causality was unclear.^[2] Those concerns cannot be resolved by vial-strength math. Identity, purity, sterility, excipients, concentration, storage, and route are separate from the number of milligrams printed on a vial.

A 2021 FDA-posted recall included a compounded injectable AOD-9604 product because sterility assurance was lacking. The recall was product- and lot-specific, but it illustrates why sterile-product quality and dosage arithmetic must be evaluated separately.^[8]

This AOD-9604 2 mg dosage guide separates three questions that search results often combine:

• Vial arithmetic: The page can establish concentration, U-100 conversion, vial yield, and supply counts from a 2 mg vial prepared to a 3.0 mL final volume.
• Published human research: Early studies examined oral and intravenous exposure, not the subcutaneous schedule displayed here.^[3]
• Preclinical research: Animal studies explored metabolism and tissue effects without establishing a human subcutaneous regimen.^[4][6]
• Community-reported use: The chart’s calculation schedule is descriptive and is not presented as a validated standard of care.

The exact-strength page therefore answers preparation and measurement questions while keeping clinical uncertainty visible. It does not name an ideal dose, recommend a maximum amount, or create an individualized peptide therapy plan. Evidence about a proposed mechanism of action cannot replace route-specific human safety and efficacy data for this research peptide.

The chart uses once-daily timing and phased calculation periods as community-reported context. Controlled human research has not established a best time to take AOD-9604, an AOD-9604 cycle length, or a preferred subcutaneous injection schedule.

Human studies evaluated other routes and protocols, while FDA’s current assessment found no human information for proposed subcutaneous use.^[1][3] The displayed schedule should therefore be read as calculation context rather than a clinically validated regimen.

Preparation for the displayed concentration uses 3.0 mL of bacteriostatic water: direct the liquid slowly down the vial wall, swirl or roll without shaking, then label and refrigerate at 2–8 °C while protecting the vial from light.

• Record the compound name, 2 mg vial strength, 3.0 mL final volume, approximately 0.667 mg/mL concentration, and preparation date.
• Inspect the container and solution against the product’s lot-specific instructions; appearance alone cannot confirm identity, sterility, or stability.
• Follow the exact label and validated documentation for storage and discard instructions. Do not transfer a use-by period from another strength, concentration, preservative system, or supplier.
• The linked Pure Lab Peptides record identifies the research-vial source used for this strength-specific calculation.^[11]

General subcutaneous-injection references describe aseptic preparation, appropriate sites, and systematic site rotation; they do not validate AOD-9604 or the schedule on this page. MedlinePlus advises using a new needle and syringe, cleaning the selected site, and rotating locations to reduce repeated tissue injury.^[9]

• Confirm that the syringe is U-100 before applying this page’s conversion.
• Distinguish 45 units from 0.45 mL and 75 units from 0.75 mL; units are volume markings.
• Do not reuse needles or syringes. Place used sharps directly into an appropriate container and follow local disposal requirements.^[10]
• Injection-technique information cannot determine whether an investigational substance is appropriate, safe, effective, or permitted.

The World Anti-Doping Agency includes AOD-9604 and hGH 176-191 as examples of prohibited growth-hormone fragments under section S2 of its Prohibited List.^[12] Athletes subject to anti-doping rules should not infer permissibility from a research label, online availability, or the absence of an approved medical indication.

Anti-doping status is separate from safety and efficacy. A prohibited-list entry does not validate a dose, and an educational calculation page does not provide a therapeutic-use exemption or sport-specific compliance advice.

What concentration results from mixing a 2 mg vial with 3 mL?

The concentration is approximately 0.667 mg/mL, or 667 mcg/mL. One U-100 unit therefore contains approximately 6.67 mcg.

How many U-100 units equal 300 mcg?

At 0.667 mg/mL, 300 mcg is approximately 0.45 mL, which equals 45 units on a U-100 syringe.

How many U-100 units equal 500 mcg?

At the same concentration, 500 mcg (0.5 mg) is approximately 0.75 mL, which equals 75 U-100 units.

How many 500 mcg calculations are in one 2 mg vial?

Four. This is a vial-yield calculation only and does not establish an appropriate administration amount or schedule.

Is the displayed schedule an approved AOD-9604 regimen?

No. The chart presents a community-reported calculation schedule. FDA has not approved AOD-9604, and published human research does not validate this subcutaneous schedule.^[1][3]

Did human trials establish AOD-9604 as a weight-loss drug?

No approved weight-loss indication resulted from the development program. An official later trial protocol states that phase 2 obesity studies did not demonstrate statistically significant weight loss compared with placebo and that development for obesity was discontinued.^[5]

Why is this page different from the 5 mg AOD-9604 page?

The 2 mg and 5 mg vials produce different concentrations, U-100 conversions, vial yields, and supply requirements when prepared to the same 3.0 mL final volume.

This page is an educational research reference and does not provide medical advice, diagnosis, treatment, or an individualized dose. The 300 mcg and 500 mcg rows are a community-reported calculation framework. They are not an FDA-approved regimen, and the academic sources below should not be interpreted as validation of subcutaneous AOD-9604 use.

• 1
  U.S. Food and Drug Administration (2024) - Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances.

  View Source
• 2
  U.S. Food and Drug Administration - AOD-9604 entry in the list of bulk substances that may present significant safety risks.

  View Source
• 3
  Journal of Endocrinology and Metabolism (2013) - Safety and tolerability summary of six AOD-9604 human trials.

  View Source
• 4
  Hormone Research (2000) - Metabolic study of AOD-9604 in obese Zucker rats.

  View Source
• 5
  ClinicalTrials.gov - NCT05298306 - Official LAT8881 protocol describing the earlier AOD-9604 obesity-development outcome.

  View Source
• 6
  Endocrinology (2001) - AOD-9604, lipid metabolism, and beta-3 adrenergic-receptor research in obese and knockout mice.

  View Source
• 7
  Annals of Clinical and Laboratory Science (2015) - Intra-articular AOD-9604 research in a rabbit osteoarthritis model.

  View Source
• 8
  U.S. Food and Drug Administration (2021) - Product- and lot-specific recall involving compounded injectable AOD-9604 and sterility assurance.

  View Source
• 9
  MedlinePlus Medical Encyclopedia - General subcutaneous-injection preparation, site, and rotation guidance.

  View Source
• 10
  U.S. Food and Drug Administration - Sharps disposal guidance for used needles and syringes.

  View Source
• 11
  Pure Lab Peptides - AOD-9604 research-vial supplier record used for the strength-specific calculation.

  View Source
• 12
  World Anti-Doping Agency (2026) - Prohibited List covering growth-hormone fragments, including AOD-9604 and hGH 176-191.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.